Cancer Immunology Immunotherapy, 2015, Vol.64 (10), p.1271-1286
Regulatory T cell (Treg)-mediated immunosuppression is considered a major obstacle for successful cancer immunotherapy. The association between clinical outcome and Tregs is being studied extensively in clinical trials, but unfortunately, no consensus has been reached about (a) the markers and (b) the gating strategy required to define human Tregs in this context, making it difficult to draw final conclusions. Therefore, we have organized an international workshop on the detection and functional testing of Tregs with leading experts in the field, and 40 participants discussing different analyses and the importance of different markers and context in which Tregs were analyzed. This resulted in a rationally composed ranking list of “Treg markers”. Subsequently, the proposed Treg markers were tested to get insight into the overlap/differences between the most frequently used Treg definitions and their utility for Treg detection in various human tissues. Here, we conclude that the CD3, CD4, CD25, CD127, and FoxP3 markers are the minimally required markers to define human Treg cells. Staining for Ki67 and CD45RA showed to provide additional information on the activation status of Tregs. The use of markers was validated in a series of PBMC from healthy donors and cancer patients, as well as in tumor-draining lymph nodes and freshly isolated tumors. In conclusion, we propose an essential marker set comprising antibodies to CD3, CD4, CD25, CD127, Foxp3, Ki67, and CD45RA and a corresponding robust gating strategy for the context-dependent analysis of Tregs by flow cytometry.
Animals ; Antigens, CD - metabolism ; Biomarkers - metabolism ; Cancer Research ; Cell Separation ; Cells ; Cells, Cultured ; Consensus ; Female ; Flow Cytometry ; Forkhead Transcription Factors - metabolism ; Humans ; Immunology ; Immunotherapy ; International Cooperation ; Ki-67 Antigen - metabolism ; Lymphocyte Activation ; Medicine & Public Health ; Monitoring ; Monitoring, Immunologic ; Oncology ; Original ; Ovarian Neoplasms - immunology ; Phenotyping ; Reference Standards ; T cells ; T-Lymphocytes, Regulatory - immunology ; Tregs ; Tumor Escape
Alma/SFX Local Collection
Permalink to record
https://www.ncbi.nlm.nih.gov/pubmed/26122357$$D View this record in MEDLINE/PubMed